跳至主要内容
临床试验/NCT02785718
NCT02785718Unknown不适用

The Influence of the Proteins of the Contact Activation System on Thrombus Formation in Human Blood

Hospices Civils de Lyon2 个研究点 分布在 1 个国家目标入组 18 人开始时间: 2015年6月最近更新:
适应症

试验速览

阶段
不适用
入组人数
18
试验地点
2
主要终点
fibrinolytic degradation rate of the formed clots by ROTEM analysis

研究概览

简要总结

Cardiovascular diseases are important causes of morbidity and mortality in the industrialized world. Abnormalities in the coagulation system, causing a hypercoagulable state, are a known risk factor for arterial and venous thrombosis. The contact activation system is part of the coagulation system and consists of four proteins: coagulation factor XII (FXII), FXI, prekallikrein and high molecular weight kininogen (HMWK). Clinical studies indicate an important role for the contact activation system on the risk of arterial thrombosis. Furthermore, there is substantial evidence from mouse studies that FXII and FXI participate in the formation and stability of thrombi. In vitro studies show that collagen, present in the vascular wall, is able to activate FXII and hereby stimulate thrombin formation and potentiate the formation of platelet-fibrin thrombi and FXIIa is able to change the structure of fibrin clots by binding to fibrin(ogen) and by generation of additional thrombin. However, the contact system also participates in the process of fibrinolysis, which degrades thrombi.

The investigators would like to investigate the contribution of the contact activation system to the formation of thrombi. The formation of a thrombus within the vascular bed is the main cause for occlusion of an artery or vein, which can lead to an infarct such as a heart attack. Due to the other functions of the contact system it is important to fully understand how the contact system contributes to thrombus formation, before it can be used as a target in the treatment of arterial thrombosis. The aim of this study is to determine the contribution of the proteins of the contact system, mainly FXII and FXI, in the platelet mediated formation and degradation of thrombi. This will be studied in flow models (perfusion-flow model and Chandler loop), in a static model (ROTEM®) and using thrombin generation assay.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Deficiency in coagulation factor XII and factor XI (factor level<5%)
  • Subjects of both gender
  • Age ≥18 and ≤ 65
  • Written informed consent from the subject
  • Subject with a social security plan or beneficiary of such a plan.

排除标准

  • Age below 18
  • Age above 65
  • Other known abnormalities of the coagulation system
  • Thrombocytopenia
  • Known platelet disorders
  • Personal history of severe liver diseases
  • Symptoms of active disease (e.g. cancer)
  • The use of antiplatelet drugs
  • The use of drugs that interfere with coagulation
  • Ongoing diagnosed pregnancy upper 3 months
  • Adult patients protected by law
  • Concomitant participation to a biomedical research

结局指标

主要结局

fibrinolytic degradation rate of the formed clots by ROTEM analysis

时间窗: 1 day (cross sectional)

次要结局

  • the ex-vivo formation of platelet-mediated thrombi on collagen in a perfusion flow mode(1 day (cross sectional))
  • biochemical composition of the thrombi formed in the Chandler loop(1 day (cross sectional))
  • endogenous thrombin potential (ETP) of the platelet rich plasma of these patients(1 day (cross sectional))

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验